Apogee Therapeutics, Inc. APGE 深 沪
等待开盘 05-19 09:30:00 美东时间
80.12
-1.020
-1.26%
华盛通- 最 高82.00
- 今 开81.46
- 成交量 26.13万股
- 最 低 78.64
- 昨 收 81.14
- 总市值 60.40亿
- 52周最高 95.315
- 市盈率 静 --
- 换手率 0.35%
- 52周最低 34.34
- 委 比 30.85%
- 总股本 7538.94万
- 历史最高 95.315
- 量 比 0.69
- 振 幅 4.14%
- 历史最低 14.19
- 每 手 1
- 风险率 18.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Apogee Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.
Apogee Therapeutics shares are trading higher after the company reported better...
05-11 22:53
Apogee Therapeutics Q1 EPS $(1.06) Beats $(1.08) Estimate
Apogee Therapeutics (NASDAQ:APGE) reported quarterly losses of $(1.06) per share which beat the analyst consensus estimate of $(1.08) by 1.85 percent. This is a 11.58 percent decrease over losses of $(0.95) per share
05-11 19:38
美股大行评级 | 苹果获多家机构上调目标价，最高至335美元；闪迪获华尔街大行看多至2000美元
今日重点评级关注：Benchmark：维持史密斯微软件"买入"评级，目标价从2美元升至2.5美元；Citizens：维持DBV Technologies"跑赢大市"评级，目标价从47美元升至55美元
05-04 16:04
Rothschild & Co Initiates Coverage On Apogee Therapeutics with Buy Rating, Announces Price Target of $140
Rothschild & Co analyst Qize Ding initiates coverage on Apogee Therapeutics (NASDAQ:APGE) with a Buy rating and announces Price Target of $140.
05-01 19:53
美股大行评级 | 潜在涨幅172.14%！Alumis获Oppenheimer上调目标价至55美元；摩根大通首予希捷科技"超配"评级，目标价525美元
今日重点评级关注：Oppenheimer：维持Alumis"跑赢大市"评级，目标价从50美元升至55美元；美银证券：维持Rocket Pharmaceuticals"买入"评级，目标价从8美元升至9美元
03-31 16:30
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
Guggenheim Maintains Buy on Apogee Therapeutics, Raises Price Target to $160
Guggenheim analyst Seamus Fernandez maintains Apogee Therapeutics (NASDAQ:APGE) with a Buy and raises the price target from $130 to $160.
03-24 19:32
美股牛股 | 太空概念Satellogic单日暴涨38%！日本在线支付商PayPay上市累涨超50%
太空概念Satellogic单日暴涨38%！将于今日举办NASA供应商研讨会；日本在线支付商PayPay隔夜再升21%，上市累涨超50%>>
03-24 18:51
Apogee Announces $300M Stock Offering
In addition, Apogee expects to grant the underwriters a 30-day option to purchase up to an additional $45 million of shares of its common stock at the public offering price, less underwriting discounts and commissions.
03-24 04:02
美股大行评级 | 超多下调！露露乐蒙、Oklo、腾讯音乐、Docusign、BOBS、Bicycle、Academy Sports等遭多家大行下调目标价
今日重点评级关注：花旗：维持Candel Therapeutics"买入"评级，目标价从22美元升至26美元；Chardan Capital：维持CervoMed"买入"评级，目标价从15美元升至21美元
03-19 14:31
